Syndax Pharmaceuticals (SNDX) Short-term Investments (2015 - 2026)

Syndax Pharmaceuticals' Short-term Investments history runs 12 years deep, the most recent figure standing at $221.2 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 5273.45% year-over-year to $221.2 million; the TTM figure through Mar 2026 stood at $221.2 million (up 5273.45% YoY), while the FY2025 annual figure was $259.1 million, up 2483.91% from the prior year.
• Short-term Investments was $221.2 million for Q1 2026 at Syndax Pharmaceuticals, down from $259.1 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $374.9 million in Q1 2023 to a low of $115000.0 in Q4 2022.
• Historically, Short-term Investments has averaged $185.1 million across 5 years, with a median of $246.6 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Short-term Investments jumped 239294.78% in 2023, then sank 98.71% in 2025.
• A 5-year view of Short-term Investments shows it stood at $115000.0 in 2022, then surged by 239294.78% to $275.3 million in 2023, then slumped by 96.36% to $10.0 million in 2024, then surged by 2483.91% to $259.1 million in 2025, then fell by 14.65% to $221.2 million in 2026.
• The last three Short-term Investments figures came in at $221.2 million (Q1 2026), $259.1 million (Q4 2025), and $18.2 million (Q3 2025), per Business Quant data.